Cingulate Inc. filings document a clinical-stage biopharmaceutical issuer with Nasdaq-listed common stock and warrants exercisable for common stock under CINGW. Recent material-event reports and proxy materials cover capital-structure actions, including private placement securities, Series A Convertible Preferred Stock, warrant exercise mechanics, debt-for-equity issuances, and shareholder votes required under Nasdaq rules.
The filing record also documents board and committee appointments, director compensation arrangements, material agreements, operating and financial results, and security-structure disclosures. These records frame Cingulate’s PTR™ drug-delivery platform and CTx-1301 program alongside formal disclosures on governance, financing arrangements, and the company’s public security structure.
Director Jeffrey S. Ervin of Cingulate has been granted 15,000 stock options on June 20, 2025. The options have the following key terms:
- Exercise price set at $4.14 per share
- Expiration date of June 20, 2035 (10-year term)
- Vesting occurs at the earlier of:
- One-year anniversary of grant date
- Date of Cingulate's 2026 annual stockholder meeting
This Form 4 filing represents a standard director compensation grant, with the options providing Ervin the right to purchase common stock at the specified strike price. The grant aligns the director's interests with shareholders through long-term equity incentives.
Director John A. Roberts of Cingulate was granted 15,000 stock options on June 20, 2025. The stock options have the following key terms:
- Exercise price set at $4.14 per share
- Expiration date of June 20, 2035 (10-year term)
- Vesting occurs at earlier of: - One-year anniversary of grant date - Date of Cingulate's 2026 annual stockholder meeting
This Form 4 filing, signed by Attorney-in-Fact Shane J. Schaffer on June 23, 2025, represents standard non-employee director equity compensation. The options provide Roberts with the right to purchase up to 15,000 shares of Cingulate common stock once vested. This grant aligns the director's interests with those of shareholders through long-term equity ownership potential.
Director Peter J. Werth of Cingulate received a stock option grant for 15,000 shares of common stock on June 20, 2025. The options were granted with an exercise price of $4.14 per share and will expire on June 20, 2035.
Key terms of the option grant:
- Vesting occurs at the earlier of: one-year anniversary of grant date or the 2026 annual stockholder meeting
- Transaction reported as a Form 4 filing indicating changes in beneficial ownership
- Options were acquired at no cost ($0) as part of director compensation
The filing was signed by Shane J. Schaffer as attorney-in-fact on June 23, 2025. This equity grant appears to be part of standard director compensation arrangements and represents a new beneficial ownership position for the reporting person.